Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 478 participants.
Also called NCT01890434
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase
- Phase 3
- Enrolled
- 478 participants
- Sponsor
- Registry
-
NCT01890434 -
2013-000066-11
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Canada, Singapore
- Registry status
- Completed
Technical summary
Registry record NCT01890434. Allocation not applicable; no masking; primary purpose diagnostic. Start 2013-08-26 (actual); primary completion 2016-08-06 (actual). Results posted on 2018-05-16.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)
- Acronym
- GadaCAD 2
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- Gadobutrol (Gadavist, Gadovist, BAY86-4875)
- Lead sponsor
- Bayer
Record details
- Record id
cardio:ct-nct01890434- Content hash
ea1d50d2cfbd0b2ba73241f0738f8b3cd658be65ed8a651debeb70042ad598ed